Jiangsu Hengrui Pharmaceuticals Initiates Phase 2 Trial of HER2 ADC SHR-A1811 Combined with Immune Checkpoint Inhibitor for Urothelial Carcinoma
Strategic Introduction of Next-Generation HER2 ADC and Immune Checkpoint Inhibitor Combination Therapy
This Phase 2 clinical trial (NCT07241793) is initiated by Sun Yat-sen University to evaluate the efficacy of the combination of Jiangsu Hengrui Pharmaceuticals (600276)'s next-generation HER2-targeted antibody-drug conjugate (ADC), Trastuzumab Rezetecan (SHR-A1811), and its PD-L1 immune checkpoint inhibitor, Adebrelimab (SHR-1316). The trial is designed as a multi-center, open-label study to assess the efficacy and safety of the drugs in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC). The combination of these two drugs reflects the latest treatment paradigm, aiming to induce synergy by precisely targeting cancer cells with ADC and reactivating the body's immune response with immune oncology. It is attracting significant attention from academia and the market as it offers a next-generation treatment option with reduced side effects and improved efficacy for patients with refractory urothelial carcinoma who have shown resistance or recurrence after initial treatment.
High Unmet Medical Need in the Urothelial Carcinoma Market and Competitive Landscape
The global urothelial carcinoma treatment market is estimated at approximately $4.16 billion in 2025 and is projected to grow rapidly to approximately $14.96 billion by 2032, making it a high-value sector. However, targeted therapy options for patients who experience recurrence after platinum-based chemotherapy and existing immune oncology treatments remain limited. Currently, the most competitive drug is Enhertu (Trastuzumab Deruxtecan) from Daiichi Sankyo and AstraZeneca, which received accelerated approval from the FDA in April 2024 for HER2-positive solid tumors. Padcev (Enfortumab Vedotin), a Nectin-4 targeting ADC, is also gaining market share, so SHR-A1811 faces the challenge of demonstrating its differentiation through its unique HER2 binding affinity and superior efficacy.
Regulatory History and Commercial Partnerships of Hengrui's Pipeline
Hengrui is actively pursuing global clinical trials and technology export agreements to expand the global reach of its proprietary pipeline. Adebrelimab, used in this clinical trial, received marketing approval from China's NMPA on March 14, 2023, as a first-line treatment for small cell lung cancer (ES-SCLC), and SHR-A1811 received conditional approval from the NMPA in May 2025 for the treatment of HER2-mutated non-small cell lung cancer (NSCLC). In addition, SHR-A1811 received Orphan Drug Designation from the U.S. FDA for biliary tract cancer in 2023 and for gastric cancer in August 2025, enhancing its global development value. In particular, in September 2025, Hengrui successfully concluded a global licensing agreement with Glenmark Specialty, including an upfront payment of $18 million and total potential payments of $1.11 billion, demonstrating its technological capabilities commercially.
Investment Strategy and Market Impact Based on Clinical Success or Failure
If this trial achieves excellent objective response rate (ORR) and disease control rate (DCR) data, Hengrui will be able to maximize the value of its proprietary HER2-targeted ADC pipeline in the urothelial carcinoma field. If it demonstrates superior progression-free survival (mPFS) and a favorable safety profile compared to Enhertu, the pace of additional technology transfer to global pharmaceutical companies or the transition to a global Phase 3 clinical trial will be significantly accelerated. Conversely, if the clinical trial experiences significant adverse events, such as fatal interstitial lung disease (ILD), or fails to demonstrate efficacy, a sharp decline in pipeline value is inevitable. Investors should closely monitor the interim efficacy data and adverse event rates to be announced in the future and proactively adjust their investment risks.
This Phase 2 trial provides a short-term value opportunity by securing a new HER2-targeted option for patients with urothelial carcinoma who have failed standard treatments in the $4.16 billion urothelial carcinoma treatment market in 2025. In the market where Enhertu, which received FDA accelerated approval in April 2024, has already established a presence, if Hengrui's SHR-A1811 demonstrates clinical utility and a superior safety profile, it will act as a powerful market disruptor as a latecomer. In the medium to long term, the combination therapy with the immune checkpoint inhibitor Adebrelimab can increase the immunogenicity of urothelial carcinoma and maximize synergy, paving the way for clinical evidence for entry into the first-line treatment market. In particular, it will significantly increase the likelihood of achieving milestones in the $1.11 billion global licensing agreement with Glenmark concluded in September 2025, thereby practically demonstrating the financial value of the pipeline. The success or failure of Hengrui's clinical trial will be a measure of the credibility of Chinese ADC and immune oncology combination therapies in the global market, and will therefore be a strategic decision-making criterion for investors and researchers in the industry.
Source: ClinicalTrials.gov (api_ct)